title: Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
abstract: This study evaluated mitoxantrone and paclitaxel combination chemotherapy in the treatment of patients with metastatic breast cancer. Thirty-seven patients who had developed progressive disease after prior chemotherapy were treated with mitoxantrone (14 mg/m2) and paclitaxel (150 mg/m2) every 21 days for a maximum of six cycles. The most frequent grade 3 or 4 nonhematological toxicities were fever and nausea. Grade 4 neutropenia occurred in 71% of patients. Cardiotoxicity occurred in 2 patients, both of whom had previously received doxorubicin. Objective response was achieved in 35% of patients (5% complete response and 30% partial response) and 41% had stable disease. Median time to disease progression and median survival were 6 and 12 months, respectively. The percent of patients with an objective response was not different for those who had received prior doxorubicin or had chemotherapy in the preceding 6 months. This regimen appears to be effective and well tolerated as salvage therapy and merits further evaluation.
authors.affiliation: Bruno Cancer Baptist Medical Center, Birmingham, Alabama, USA.
authors.forename: J
authors.initials: J
authors.lastname: Harvey
authors.forename: J
authors.initials: J
authors.lastname: Cantrell
authors.forename: M
authors.initials: M
authors.lastname: Campbell
authors.forename: A
authors.initials: A
authors.lastname: Cartmell
authors.forename: W
authors.initials: W
authors.lastname: Urba
authors.forename: M
authors.initials: M
authors.lastname: Modiano
authors.forename: M
authors.initials: M
authors.lastname: Schuster
authors.forename: A
authors.initials: A
authors.lastname: Rubin
authors.forename: T
authors.initials: T
authors.lastname: Newcomb
authors.forename: R
authors.initials: R
authors.lastname: Ghalie
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D008942:Mitoxantrone; D017239:Paclitaxel